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ABSTRACT:
Protein–protein interactions (PPIs) are essential for
implementing cellular processes and thus methods for the
discovery and study of PPIs are highly desirable. An
emerging method for capturing PPIs in their native cellu-
lar environment is in vivo covalent chemical capture, a
method that uses nonsense suppression to site specifically
incorporate photoactivable unnatural amino acids
(UAAs) in living cells. However, in one study we found
that this method did not capture a PPI for which there
was abundant functional evidence, a complex formed
between the transcriptional activator Gal4 and its
repressor protein Gal80. Here we describe the factors that
influence the success of covalent chemical capture and
show that the innate reactivity of the two UAAs utilized,
(p-benzoylphenylalanine (pBpa) and p-azidophenylala-
nine (pAzpa)), plays a profound role in the capture of
Gal80 by Gal4. Based upon these data, guidelines are
outlined for the successful use of in vivo photo-
crosslinking to capture novel PPIs and to characterize the
interfaces.VC 2013 Wiley Periodicals, Inc. Biopolymers
101: 391–397, 2014.
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INTRODUCTION
P
rotein–protein interactions (PPIs) underlie virtually
all cellular functions and regulate both the location
and timing of specific activities.1–3 In the case of
gene transcription, for example, PPIs between tran-
scription factors and histone acetyl transferases such
as CBP/p300 localize the enzymatic activity of the HAT to
specific promoters, leading to transcriptional upregulation.4,5
Mis-regulation of PPIs is associated with many human dis-
eases and with the successful development of clinically rele-
vant PPI inhibitors, there is renewed interest in discovering
and characterizing PPIs with the goal of identifying new
therapeutic targets.2,6–11 Since many PPIs occur in the context
of multi-component complexes, it is particularly valuable to
carry out such studies in the native cellular environment.
We recently described the implementation of a powerful
approach that enables the study of PPIs in vivo, a strategy that
uses nonsense suppression to site-specifically incorporate a
photoactivatable amino acid into a protein of interest in Sac-
charomyces cerevisiae (Figure 1).12,13 Photo-crosslinking is then
carried out with live cells, enabling the capture of protein bind-
ing partners in their native context. Our first example lead to
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the in situ characterization of the binding interface between the
transcriptional activator Gal4 and its masking protein Gal80.
For these experiments, the unnatural amino acid p-benzoyl-L-
phenylalanine (pBpa) was incorporated into 10 different posi-
tions within the transcriptional activation domain of Gal4 and
photo-crosslinking was carried out in living yeast under condi-
tions in which Gal80 was expected to bind Gal4. While we
detected complex formation via in vivo crosslinking at most
positions, we noted several instances where functional data
and existing structural data for the Gal4–Gal80 complex sup-
ported a direct interaction yet little to no crosslinking was
observed.12,14–18 For example, Phe856 has been observed in
structural studies to be buried within the Gal4•Gal80 binding
interface.17,18 When Phe856 was replaced with pBpa, the result-
ing Gal4 mutant was repressed in the presence of Gal80, sug-
gesting that the mutation did not negatively impact the Gal80
binding interaction, yet no Gal4–Gal80 covalent complex could
be observed after crosslinking.
A negative result in an in vivo photo-crosslinking experiment
could arise from a variety of factors, including the lack of a bind-
ing interaction, low unnatural amino acid (UAA) incorporation
yield and/or fidelity, poor positioning of the UAA, and the poor
reactivity of the activated UAA with the amino acids in the bind-
ing partner. In the case of the Phe856pBpa Gal4 mutant, there
was functional evidence excluding the lack of a binding interac-
tion as an explanation. Here we describe an examination of the
remaining facets of the in vivo crosslinking experiment and,
importantly, demonstrate the substantial role that the crosslink-
ing mechanism and the sequence context play in the ability to
capture a PPI. This case study of a PPI provides a framework for
designing successful in vivo crosslinking experiments.
RESULTS AND DISCUSSION
Gal4 is a well-characterized transcriptional activator that regu-
lates genes responsible for galactose catabolism in yeast and its
function is highly regulated by the inhibitory protein,
Gal80.14–16,19 In the presence of glucose, Gal80 binds Gal4
tightly, thus preventing Gal4 from recruiting the necessary
transcriptional complexes to upregulate gene expression. Con-
versely, in the absence of glucose and in the presence of galac-
tose, inhibition of Gal4 by Gal80 is lifted, allowing
transcription to occur. We chose to use this well-characterized
interaction as a predictable model under which we could eval-
uate the impact of UAA incorporation on activator binding
and function. Furthermore, extensive biochemical and struc-
tural studies have provided information on the key residues in
Gal4 involved in directly contacting Gal80, thus mapping out
FIGURE 1 A schematic of in vivo crosslinking utilizing UAAs such as pBpa and pAzpa. In this
strategy, nonsense suppression is used to incorporate the UAA of choice into the protein. Subse-
quent UV irradiation leads to activation of the UAA, enabling it to form crosslinks with nearby
binding partners. The crosslinked complexes can then be analyzed by Western blot as indicated or
by techniques such as mass spectrometry. Factors influencing the success of the overall strategy
include efficient incorporation of the UAA (affected by UAA availability and expression of the
tRNA/tRNAsynthetase pair) and the identity of the UAA as well as its positioning within the
protein.
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positions where pBpa incorporation was most likely to yield
crosslinks.17,18,20,21 As in previous reports, a heterologous con-
struct was utilized in which the transcriptional activation
domain of Gal4 (residues 840–881) was fused to the LexA
DNA binding domain (LexA1Gal4). The advantage of this
construct is a single promoter containing binding sites for
LexA exists within the yeast strain used in our studies (LS41),
simplifying functional analyses of all mutant proteins.12 Addi-
tionally, a FLAG tag at the c-terminus of the construct facili-
tates purification and detection.
As described by us and others, the fidelity and efficiency of
UAA incorporation can vary significantly with protein and
amino acid position.12,22 Additionally, efficient incorporation
of an UAA requires the UAA, a tRNA for that amino acid, and
a synthetase (RS) to charge the tRNA. Thus, the expression of
these components is an important variable in the successful
implementation of the nonsense suppression strategy. In our
initial studies, little to no incorporation of pBpa was observed
for LexA1Gal4 using the originally reported expression sys-
tem.12,23 Upon alteration of the tRNA/RS copy number and
the promoter controlling expression of these elements, we
found that pBpa incorporation was increased, although this
also lead to some loss in incorporation fidelity. However, we
also tested an expression system developed by Wang and
Wang that utilizes a PolIII promoter (pSNR52) containing
consensus A and B box sequences to control tRNA expres-
sion.22 As determined by Western blot and functional experi-
ments, use of the Wang tRNA expression system resulted in
the best yield with high fidelity of a LexA1Gal4 construct in
which Phe849 has been replaced with pBpa (Figure 2a). Fur-
ther efforts to optimize this system demonstrated that nei-
ther increasing the concentration of pBpa in the growth
media beyond 1 mM nor adding a premature stop codon
suppressor (PTC124) increased yield significantly (Figures
2b–2d). Thus, for incorporation experiments with transcrip-
tional activators, we find the optimal conditions to include
use of a system that employs eukaryotic pol III promoter ele-
ments to drive the expression of multi-copy tRNA/RS genes
for incorporation of UAAs provided at a concentration of
1 mM in yeast growth media.
FIGURE 2 Optimal conditions for expression of pBpa mutants of LexA1Gal4. (a) The efficiency
of pBpa incorporation under various tRNA/synthetase expression systems was assessed by b-
galactosidase assays. In this system the amount of activity, which is the average values of three inde-
pendent experiments with the indicated error (SDOM), is related to the expression of full-length
LexA1Gal4 in which Phe849 was replaced with pBpa.22,24,25 The LS41 yeast strain used for this
study bears an integrated b-galactosidase reporter controlled by two LexA binding sites approxi-
mately 50 bp upstream of the transcription start site. Among the combinations evaluated, the
pSNR52 tRNA/aaRS system (red box) in which the expression plasmid carried two copies of both
the tRNA and the synthetase (blue box) provided the best yield of LexA1Gal4 Phe849pBpa. (b)
The effect of pBpa concentration in the growth media on incorporation yield was assessed via
quantitated Western blot (a-FLAG) of LexA1Gal4 Phe849pBpa bearing a FLAG tag at the C-
terminus. The % yield of LexA1Gal4 Phe849pBpa mutant relative to WT LexA1Gal4 is indicated.
To account for loading variations, each band was normalized to a-tubulin. (c) A Western blot (a-
FLAG) comparison of LexA1Gal4 Phe849pBpa expressed with different tRNA/tRNAsynthetase
expression systems. The % yield of LexA1Gal4 Phe849pBpa mutant is calculated relative to WT
LexA1Gal4. To account for loading variations, each band was normalized to a-tubulin. (d) A West-
ern blot (a-FLAG) comparison of LexA1Gal4 Phe849pBpa expressed in the presence of increasing
concentrations of PTC124. Additional details can be found in the Methods section.
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Covalent Capture with LexA1Gal4
As described earlier, when in vivo crosslinking was carried out
with LexA1Gal4 Phe856Bpa no complex between Gal4 and
Gal80 was observed despite several lines of experimental and
literature evidence supporting an interaction. Believing that
this may be due to poor expression of the mutant Gal4, we
evaluated pBpa incorporation at position 856 using the opti-
mized incorporation conditions outlined in the previous sec-
tion. Subsequent Western blot analysis and functional data
indicated that LexA1Gal4 Phe856pBpa was not only being
expressed, but that it was also fully functional and sensitive to
Gal80 inhibition in the presence of glucose (Figure 3a,b).
Thus, we examined other parameters that would produce a
negative result, focusing on the crosslinking mechanism of
pBpa in addition to a second photo-crosslinking UAA, p-azi-
dophenylalanine (pAzpa).
pBpa forms a diradical upon UV irradiation at 350–365 nm
and then undergoes a CAH insertion reaction with nearby
backbones and amino acid side chains.26Although pBpa is
capable of inserting into most CAH bonds, experimentally
pBpa reacts preferentially with methionine (Met) where it will
react at distances beyond the 3.1 A˚ reactivity radius.27 Specifi-
cally, the apparent preference of pBpa for methionine suggests
that pBpa efficiency can be altered dramatically when placed
in close proximity to methionine’s thioether side chain.27–29
Further examination of position 856 in the Gal4 TAD reveals
two methionines in close proximity to the pBpa side chain;
thus, we hypothesized that these methionines at positions 855
and 861 are internally “quenching” pBpa, thereby preventing it
from crosslinking to Gal80. Consistent with this hypothesis,
when Met855 and Met861 are mutated either individually or
collectively to alanine, we see that the resulting mutants are
functional and, importantly, that pBpa crosslinking to Gal80 is
restored (Figure 3a–c). These data are consistent with a model
in which an intramolecular crosslink was competing with the
intermolecular reaction in the LexA1Gal4 Phe856pBpa mutant
and lead to a false negative in our original experiments.
A second photoactivable UAA that can be incorporated into
proteins in S. cerevisiae using the nonsense suppression
method is pAzpa. The amino acid preference for pAzpa cross-
linking is less clear because it has a more complex crosslinking
mechanism compared to pBpa.26 During excitation at 254
nm light it forms a nitrene and it is at this state that insertion
into CAH or heteroatom-H bonds occurs. If, however, inser-
tion does not take place during the 1024 s excitation (deter-
mined for simple nitrenes in a polystyrene matrix) it will
rearrange to a more stable ketenimine.26,30 Once rearranged,
the ketenimine reacts with nucleophiles. While these differen-
ces in crosslinking reactivity between pBpa and pAzpa are
known, a direct comparison of the effect of these reactivities
FIGURE 3 The effect of methionine on LexA1Gal4 F856pBpa crosslinking to Gal80. (a) Expres-
sion of LexA1Gal4 F856pBpa as detected by Western blot of cell lysates with a-Flag. (b).The activa-
tion potential of each mutant was measured by liquid b-galactosidase assays. In the yeast strain
tested, b-galactose expression was controlled by a Gal1 promoter containing two LexA binding sites
for LexA1Gal4 binding. (c) Crosslinking of LexA1Gal4 F856pBpa to myc-tagged Gal80 as shown
by Western blot of cell lysates with a-Myc antibody.
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on the experimental outcome of crosslinking studies has yet to
be established. Utilization of the expression conditions out-
lined earlier lead to the incorporation of pAzpa at position 856
and the resulting mutant was fully functional (Figures 4a and
4b). A direct comparison of pAzpa and pBpa crosslinking at
position 856 reveals that pAzpa crosslinks readily with Gal80
whereas pBpa does not (Figure 4c). As expected, introduction
of alanine at positions 855 and 861 yielded no changes in Azpa
crosslinking, consistent with the reactivity profile of this amino
acid. These data indicate that the difference in reactive mecha-
nisms of crosslinkers play a critical role in the outcome of
crosslinking experiments.
CONCLUSIONS
Although the Gal4•Gal80 PPI that is the focus of this study is a
well-characterized complex, the present and future applications
of in vivo covalent capture are to discover previously unknown
PPIs. The results shown here illustrate that not only is optimi-
zation of UAA incorporation a key factor in successful applica-
tion of the strategy, but careful consideration of the innate
reactivity of the UAA utilized is also critical. The longer lifetime
and lower reactivity toward solvent makes pBpa an attractive
choice, particularly for PPIs that occur through shallow,
exposed binding sites. However, the marked preference of
pBpa for methionine raises some concern that crosslinking
results could be influenced by the presence of methionine in
the UAA-containing protein as shown here or by a lack of
methionines in potential binding partners.31 In other words,
relevant binding partners could be missed in an unbiased study
due to either of these factors. To avoid false negatives, it is criti-
cal to carry out crosslinking with more than a single UAA
mutant, since, as illustrated here and in a previous study, a
small change in position can have a dramatic effect on cross-
linking. Additionally, it is most useful to use more than one
UAA in a study. In the case of Gal4•Gal80, the use of the UAA
pAzpa at position 856 within Gal4 restored crosslinking with
Gal80. Applying the considerations presented here will facili-
tate the successful implementation of in vivo covalent chemical
capture for studying PPIs involved in a variety of biological
processes.
METHODS
LS41 [JPY9::pZZ41, Matahis3D200 leu2D1 trp1D63 ura3–52 lys2D385
gal4 URA::pZZ41] yeast was used for all experiments. pBpa was pur-
chased from Chem-Impex International (Wood Dale, IL). pAzpa was
purchased from Bachemand Chem-Impex (Torrance, CA). All plas-
mids described below were constructed using standard molecular
biology techniques and the sequences of all the isolated plasmids were
FIGURE 4 Neighboring methionines have little effect on LexA1Gal4 F856Azpa crosslinking to
Gal80. (a) Expression of LexA1Gal4 F856Azpa as detected by Western blot of cell lysates with a-
Flag antibody. (b) The activation potential of each mutant was measured by liquid beta-
galactosidase assays as in Figure 3. Each value is the average of at least three independent experi-
ments with the indicated error (SDOM). (c) Crosslinking of LexA1Gal4 F856Azpa to myc-Gal80
as shown by Western blot of cell lysates with a-Myc antibody. See Methods for details.
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verified by sequencing at the University of Michigan Core Facility
(Ann Arbor, MI).
Incorporation of pBpa or pAzpa into LexA(1–
202)1Gal4(840–881)
LS41 yeast were transformed with pLexAGal4849 TAG mutants and
either pSNRtRNA-pBpaRS or pSNRtRNA-pAzpaRS plasmid. A single
colony of transformed LS41 was inoculated in a 4 mL synthetic drop-
out yeast media lacking histidine, tryptophan, and uracil containing
2% raffinose and grown overnight at 30C. These starter cultures were
used to inoculate a set of expression cultures made of 4 mL synthetic
dropout media lacking His, Trp, and Ura plus 2% raffinose, 2% galac-
tose, 10 mM HCl and either 10 mM NaOH for cultures lacking UAA
or 1 mM UAA in 10 mM NaOH. Cultures were grown to mid-log
phase OD660 and 3 OD’s of cells were collected, washed with sterile
DI water, and snap frozen in liquid nitrogen. Pellets were then lysed
with pellet lysis buffer (50 mM Tris acetate pH 7.9, 150 mM KOAc,
20% glycerol, 0.2% Tween 20, and 2 mM MgOAc) including DTT and
NuPAGE lithium dodecyl sulfate loading dye and boiled at 95C for
10 min. Lysates were loaded onto an 8% Tris-acetate gel and run in
Tris-acetate running buffer (Invitrogen). Proteins were then trans-
ferred to polyvinyl difluoride using a semi-dry transfer apparatus,
blocked in 5% milk in phosphate buffered saline and Tween-20
(PBST), and then incubated with a 1:1000 dilution of a-Flag-
horseradish peroxidase antibody (Sigma) to detect full length Lex-
A1Gal4. In the case of the PTC124 (MedChem Express) experiments,
varying concentrations of PTC124 (0, 0.1, 1, and 10 mM) was first dis-
solved in Dimethyl sulfoxide and then added to expression cultures.
Western Blot Quantitation
The quantitation of the LexA-Gal4 protein levels was performed on a
representative Western Blot using the Adobe Photoshop method as
previously reported by Miller et al.32 Here, for each lane, the
LexA1Gal4 protein, detected by an anti-FLAG antibody, (1:5000,
Sigma M2) was normalized to that of a-Tubulin. a-Tubulin was
detected using a monoclonal a-Tubulin antibody, YL1/2 (1:5000,
Santa Cruz Biotechnologies), the blots were developed using a horse-
radish peroxidase-conjugated secondary antibody (1:20,000, Santa
Cruz Biotechnologies) and then visualized by chemiluminescence
with ECL plus (GE Healthcare). The relative amount of LexA-Gal4
protein for each experiment was expressed as follows ((experimental
value/WT LexA-Gal4)3 100).
b-Galactosidase Assays
To evaluate the ability of each LexA1Gal4 TAG mutant to activate
transcription, in the absence or presence of 1 mM or 2 mM pBpa, sat-
urated cultures (SC media1 2% raffinose) of each mutant were used
to inoculate 5 mL SC media lacking histidine, uracil, and tryptophan
supplemented with 2% glucose or 2% raffinose1 2% galactose or 2%
raffinose and grown to mid-log phase OD660 before being harvested.
The activity of each construct was monitored using a liquid b-
galactosidaseprotocol, previously described by our group.12
In Vivo Photo-crosslinking
In vivo photo-crosslinking experiments were carried out as previously
reported.12,13
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